Kamada (KMDA) Competitors

In the previous week, Taysha Gene Therapies had 5 more articles in the media than Kamada. MarketBeat recorded 10 mentions for Taysha Gene Therapies and 5 mentions for Kamada. Kamada's average media sentiment score of 0.17 beat Taysha Gene Therapies' score of -0.10 indicating that Kamada is being referred to more favorably in the media.

20.4% of Kamada shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kamada has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Kamada has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.

Kamada currently has a consensus price target of $13.00, indicating a potential upside of 52.05%. Taysha Gene Therapies has a consensus price target of $11.64, indicating a potential upside of 70.87%. Given Taysha Gene Therapies' higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Kamada.

Kamada has a net margin of 11.19% compared to Taysha Gene Therapies' net margin of 0.00%. Kamada's return on equity of 7.72% beat Taysha Gene Therapies' return on equity.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 3 more articles in the media than Kamada. MarketBeat recorded 8 mentions for Lakefront Biotherapeutics American Depositary Shares and 5 mentions for Kamada. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.79 beat Kamada's score of 0.17 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

20.4% of Kamada shares are owned by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Kamada. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

Kamada has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.25, suggesting that its share price is 75% less volatile than the S&P 500.

Kamada currently has a consensus price target of $13.00, indicating a potential upside of 52.05%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, indicating a potential upside of 27.67%. Given Kamada's stronger consensus rating and higher possible upside, research analysts plainly believe Kamada is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Kamada has a net margin of 11.19% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Kamada's return on equity of 7.72% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Kamada has a net margin of 11.19% compared to Amylyx Pharmaceuticals' net margin of 0.00%. Kamada's return on equity of 7.72% beat Amylyx Pharmaceuticals' return on equity.

In the previous week, Amylyx Pharmaceuticals had 2 more articles in the media than Kamada. MarketBeat recorded 7 mentions for Amylyx Pharmaceuticals and 5 mentions for Kamada. Kamada's average media sentiment score of 0.17 beat Amylyx Pharmaceuticals' score of -0.11 indicating that Kamada is being referred to more favorably in the news media.

Kamada has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.4% of Kamada shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 36.1% of Kamada shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Amylyx Pharmaceuticals presently has a consensus price target of $23.00, suggesting a potential upside of 56.14%. Kamada has a consensus price target of $13.00, suggesting a potential upside of 52.05%. Given Amylyx Pharmaceuticals' higher probable upside, equities analysts plainly believe Amylyx Pharmaceuticals is more favorable than Kamada.

Amylyx Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, Kamada has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Amylyx Pharmaceuticals pays an annual dividend of $1.0160 per share and has a dividend yield of 6.9%. Kamada pays an annual dividend of $0.18 per share and has a dividend yield of 2.1%. Amylyx Pharmaceuticals pays out -67.7% of its earnings in the form of a dividend. Kamada pays out 51.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amylyx Pharmaceuticals is clearly the better dividend stock, given its higher yield and lower payout ratio.

Kamada presently has a consensus price target of $13.00, suggesting a potential upside of 52.05%. Syndax Pharmaceuticals has a consensus price target of $42.64, suggesting a potential upside of 98.40%. Given Syndax Pharmaceuticals' higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Kamada.

20.4% of Kamada shares are held by institutional investors. 36.1% of Kamada shares are held by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Kamada has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Kamada has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.

In the previous week, Syndax Pharmaceuticals had 9 more articles in the media than Kamada. MarketBeat recorded 14 mentions for Syndax Pharmaceuticals and 5 mentions for Kamada. Syndax Pharmaceuticals' average media sentiment score of 0.55 beat Kamada's score of 0.17 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Kamada has a net margin of 11.19% compared to Syndax Pharmaceuticals' net margin of -111.88%. Kamada's return on equity of 7.72% beat Syndax Pharmaceuticals' return on equity.